Immune-Boosting drug could help fight High-Risk thyroid cancer before surgery
NCT ID NCT05852223
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving the drug pembrolizumab before thyroid surgery can help the immune system attack high-risk differentiated thyroid cancer. About 25 adults with a high chance of cancer returning will receive two doses of pembrolizumab before their thyroidectomy. Researchers will study immune cells in the tumor and blood to see how the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could point toward a new treatment option for high-risk thyroid cancer before surgery.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Clinici Scientifici Maugeri
RECRUITINGPavia, Lombardy, 27100, Italy
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••